StocksMedium•19 October 2026•
1 min read
Haemonetics Receives FDA Approval for PerQseal Elite Vascular Closure System
Key Facts
1Haemonetics received U.S. FDA approval for the PerQseal Elite vascular closure system for large-bore arterial procedures.
Haemonetics received U.S. FDA approval for the PerQseal Elite vascular closure system for large-bore arterial procedures. PR Newswire reported that the approval expands the company's portfolio for structural heart and endovascular procedures, following Haemonetics' acquisition of Vivasure Medical Limited in January 2026.
HAE closed at $118.28 on October 16, 2026, with the stock reaching a day high of $121.84 and a low of $118.19 during that session. The newly approved system is designed to enhance patient outcomes in complex arterial interventions, strengthening the company's position in the interventional health technology market.